Q-omics provides the consensus-scored XKR7 profile across patient tissues and cancer cell-line models. XKR7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, XKR7 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, XKR7 RNA expression shows 16,063 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCEC, COAD, and PCPG as cancer lineages where XKR7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XKR7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XKR7 survival associations across molecular data types. XKR7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XKR7 RNA expression–survival associations across cancer types. High XKR7 expression shows unfavorable associations in UCEC, ACC, KIRP and CESC, but favorable associations in LGG and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for XKR7 RNA expression.
This table summarizes XKR7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for XKR7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XKR7 shows lower tumor expression in COAD, KICH and ESCA and higher tumor expression in KIRP, BRCA and THCA. The COAD box plot shows higher XKR7 RNA expression in normal versus tumor tissue (log2 FC = −0.081, t-test p < 0.001).
This table shows molecular features associated with XKR7 in patient tissues and cancer cell lines. In patient samples, XKR7 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, XKR7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
